Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Fidelity National Information Servcs Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Fidelity National Information Servcs Inc trades at $35.84 (market cap $18.15B). The key difference: Fidelity National Information Servcs Inc is far larger — about 6.3× Dyne Therapeutics Inc. Common Stock's market cap, and Fidelity National Information Servcs Inc pays a 5% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Fidelity National Information Servcs Inc for 89 Days on average.
| DYN | FIS | |
|---|---|---|
Market Cap | $2.86B | $18.15B |
Volume | 3,341,579 | 8,219,694 |
Sector | Health | Technology |
52-Week High | $26.78 | $67.94 |
52-Week Low | $14.60 | $32.44 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $2.18B | $38.66B |
Dividend Yield | — | 5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
FIS (Fidelity National Information Services) trades at $35.20, up 2.74% today, with a bearish technical signal but strong fundamentals including a low P/E of 5.41 and net income margin of 27.65%. Recent earnings have mostly beaten estimates, and the company is expanding its core banking and embedded finance platforms, as seen with new client wins like Kredittbanken (Business Wire, September 30, 2026).
The outlook is mixed: analyst consensus is bullish with a $45.50 price target, but risks include high debt levels and volatile cash flows. Upside potential exists from revenue growth and modernization efforts, while downside risks stem from execution challenges and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
